Rapid self-assembly of α-synuclein observed by in situ atomic force microscopy

Journal of Molecular Biology

Volumn 340, Issue 1, 2004, Pages 127-139

  Hoyer, Wolfgang ^a   Cherny, Dmitry ^a,b   Subramaniam, Vinod ^c   Jovin, Thomas M ^a  

^a MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^b INSTITUTE OF MOLECULAR GENETICS   (Russian Federation)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

AFM, atomic force microscopy; amyloid fibril; atomic force microscopy; A , Alzheimer's amyloid peptide; EPR, electron paramagnetic resonance; ESI MS, electrospray ionization mass spectrometry; soluble oligomer; synuclein; sheet

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN; POLYAMINE; SPERMIDINE; SPERMINE;

ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CRYSTALLIZATION; HYDROPHOBICITY; MONITORING; NEUROTOXICITY; PH; PRIORITY JOURNAL; PYROLYSIS; TEMPERATURE; WILD TYPE;

MICA;

EID: 2942592408     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.04.051     Document Type: Article

References (60)

1. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nature Rev. Neurosci. 2:2001;492-501
2. Goldberg M.S., Lansbury P.T. Jr. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nature Cell. Biol. 2:2000;E115-E119
3. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047
4. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nature Genet. 18:1998;106-108
5. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Jr. Amyloid pores from pathogenic mutations. Nature. 418:2002;291
6. Kim Y.S., Lee D., Lee E.K., Sung J.Y., Chung K.C., Kim J., Paik S.R. Multiple ligand interaction of α-synuclein produced various forms of protein aggregates in the presence of Aβ25-35, copper, and eosin. Brain Res. 908:2001;93-98
7. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511
8. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 300:2003;486-489
9. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., Lansbury P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 35:1996;13709-13715
10. Hashimoto M., Hsu L.J., Sisk A., Xia Y., Takeda A., Sundsmo M., Masliah E. Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res. 799:1998;301-306
11. Giasson B.I., Uryu K., Trojanowski J.Q., Lee V.M. Mutant and wild type human α-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274:1999;7619-7622
12. Serpell L.C., Berriman J., Jakes R., Goedert M., Crowther R.A. Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc. Natl Acad. Sci. USA. 97:2000;4897-4902
13. Conway K.A., Harper J.D., Lansbury P.T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry. 39:2000;2552-2563
14. Der-Sarkissian A., Jao C.C., Chen J., Langen R. Structural organization of α-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278:2003;37530-37535
15. Miake H., Mizusawa H., Iwatsubo T., Hasegawa M. Biochemical characterization of the core structure of α-synuclein filaments. J. Biol. Chem. 277:2002;19213-19219
16. Crowther R.A., Jakes R., Spillantini M.G., Goedert M. Synthetic filaments assembled from C-terminally truncated α-synuclein. FEBS Letters. 436:1998;309-312
17. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., et al. Role of α-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry. 42:2003;8530-8540
18. Paik S.R., Shin H.J., Lee J.H., Chang C.S., Kim J. Copper(II)-induced self-oligomerization of α-synuclein. Biochem. J. 340:1999;821-828
19. 2+ binding to α-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276:2001;22680-22684
20. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276:2001;44284-44296
21. Hoyer W., Antony T., Cherny D., Heim G., Jovin T.M., Subramaniam V. Dependence of α-synuclein aggregate morphology on solution conditions. J. Mol. Biol. 322:2002;383-393
22. Antony T., Hoyer W., Cherny D., Heim G., Jovin T.M., Subramaniam V. Cellular polyamines promote the aggregation of α-synuclein. J. Biol. Chem. 278:2003;3235-3240
23. Fernandez C.O., Hoyer W., Zweckstetter M., Jares-Erijman E.A., Subramaniam V., Griesinger C., Jovin T.M. NMR of α-synuclein complexes with polyamines elucidates the mechanism and kinetics of induced aggregation. EMBO J. 23:2004;2039-2046
24. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem. 276:2001;10737-10744
25. Conway K.A., Harper J.D., Lansbury P.T. Jr. Jr accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson's disease. Nature Med. 4:1998;1318-1320
26. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., et al. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J. Biol. Chem. 274:1999;9843-9846
27. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA. 97:2000;571-576
28. Li J., Uversky V.N., Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry. 40:2001;11604-11613
29. Ding T.T., Lee S.J., Rochet J.C., Lansbury P.T. Jr. Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry. 41:2002;10209-10217
30. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., Lansbury P.T. Jr. α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322:2002;1089-1102
31. Dobson C.M. Protein folding and misfolding. Nature. 426:2003;884-890
32. Goldsbury C., Kistler J., Aebi U., Arvinte T., Cooper G.J. Watching amyloid fibrils grow by time-lapse atomic force microscopy. J. Mol. Biol. 285:1999;33-39
33. Kowalewski T., Holtzman D.M. In situ atomic force microscopy study of Alzheimer's β-amyloid peptide on different substrates: new insights into mechanism of β-sheet formation. Proc. Natl Acad. Sci. USA. 96:1999;3688-3693
34. Blackley H.K., Sanders G.H., Davies M.C., Roberts C.J., Tendler S.J., Wilkinson M.J. In-situ atomic force microscopy study of β-amyloid fibrillization. J. Mol. Biol. 298:2000;833-840
35. Bailey S.W. Structures of layer silicates. Brindley G.W., Brown G. Crystal Structure of Clay Minerals and their X-ray Identification. 1980;2-196 Mineralogical Society, London
36. Crowther R.A., Daniel S.E., Goedert M. Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Letters. 292:2000;128-130
37. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., Biere A.L. α-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274:1999;19509-19512
38. DePace A.H., Weissman J.S. Origins and kinetic consequences of diversity in Sup35 yeast prion fibers. Nature Struct. Biol. 9:2002;389-396
39. Zhu M., Souillac P.O., Ionescu-Zanetti C., Carter S.A., Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277:2002;50914-50922
40. Davidson W.S., Jonas A., Clayton D.F., George J.M. Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273:1998;9443-9449
41. McLean P.J., Kawamata H., Ribich S., Hyman B.T. Membrane association and protein conformation of α-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J. Biol. Chem. 275:2000;8812-8816
42. Jo E., McLaurin J., Yip C.M., St George-Hyslop P., Fraser P.E. α-Synuclein membrane interactions and lipid specificity. J. Biol. Chem. 275:2000;34328-34334
43. Lee H.J., Choi C., Lee S.J. Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277:2002;671-678
44. Narayanan V., Scarlata S. Membrane binding and self-association of α-synucleins. Biochemistry. 40:2001;9927-9934
45. Zhu M., Fink A.L. Lipid binding inhibits α-synuclein fibril formation. J. Biol. Chem. 278:2003;16873-16877
46. Necula M., Chirita C.N., Kuret J. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 278:2003;46674-46680
47. Plank H., Resel R., Andreev A., Sariciftci N.S., Sitter H. Structural relationship between epitaxially grown para-sexiphenyl and mica (0 0 1) substrates. J. Cryst. Growth. 237-239:2002;2076-2081
48. Jaroniec C.P., MacPhee C.E., Bajaj V.S., McMahon M.T., Dobson C.M., Griffin R.G. High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. Proc. Natl Acad. Sci. USA. 101:2004;711-716
49. Yang G., Woodhouse K.A., Yip C.M. Substrate-facilitated assembly of elastin-like peptides: studies by variable-temperature in situ atomic force microscopy. J. Am. Chem. Soc. 124:2002;10648-10649
50. Cohlberg J.A., Li J., Uversky V.N., Fink A.L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry. 41:2002;1502-1511
51. Hong Y., Legge R.L., Zhang S., Chen P. Effect of amino acid sequence and pH on nanofiber formation of self-assembling peptides EAK16-II and EAK16-IV. Biomacromolecules. 4:2003;1433-1442
52. Koti A.S.R., Periasamy N. Self-assembly of template-directed J-aggregates of porphyrin. Chem. Mater. 15:2003;369-371
53. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., et al. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA. 95:1998;6448-6453
54. 1-42 fibrillogenesis. Scand. J. Immunol. 49:1999;219-223
55. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Jr. Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 38:1999;8972-8980
56. Yong W., Lomakin A., Kirkitadze M.D., Teplow D.B., Chen S.H., Benedek G.B. Structure determination of micelle-like intermediates in amyloid β-protein fibril assembly by using small angle neutron scattering. Proc. Natl Acad. Sci. USA. 99:2002;150-154
57. Serio T.R., Cashikar A.G., Kowal A.S., Sawicki G.J., Moslehi J.J., Serpell L., et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science. 289:2000;1317-1321
58. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Jr. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 40:2001;7812-7819
59. Ban T., Hamada D., Hasegawa K., Naiki H., Goto Y. Direct observation of amyloid fibril growth monitored by Thioflavin T fluorescence. J. Biol. Chem. 278:2003;16462-16465
60. Zarrane J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampyero I., et al. The new mutation E46K of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55:2004;164-173